New Agent Pralatrexate: Nursing Management and considerations on T cell Lymphoma patients receiving pralatrexate

2.50
Hdl Handle:
http://hdl.handle.net/10755/164977
Category:
Abstract
Type:
Presentation
Title:
New Agent Pralatrexate: Nursing Management and considerations on T cell Lymphoma patients receiving pralatrexate
Author(s):
Guerrero, Maria; Loggins-Coffman, Judy
Author Details:
Maria Guerrero, RN, MSN, ANP-C, AOCNP, Nurse Practitioner, MD Anderson Cancer Center, Houston, Texas, USA, email: mdguerre@mdanderson.org; Judy Loggins-Coffman, RN, MD
Abstract:
Clinical/Evidence Based Practice: T cell Lymphoma represents a group of malignancies for which there has been little progress in treatment over the past years. T cell Lymphoma not only reveals a prognosis that may be worse than B cell Lymphoma, but T cell is a rare cancer (representing 10-15% of malignant lymphoma) little consensus can be established due to difficulties in finding enough patients to enroll for appropriate clinical studies. For this reason there is a strong demand to develop drugs and treatment regimens for T cell Lymphoma. In this poster we would like to discuss the new emerging drug Pralatrexate for the treatment of T Cell Lymphoma. The purpose of this poster is to provide an educational tool that the oncology nurse briefly discuss new drug praletrexate, its role in T cell lymphoma, side effects associated with this drug, as well as nursing considerations and 1. Discuss the role of Pralatrexate in the treatment of T Cell Lymphoma 2. Common side effects associated with Praletrexate 3. Nursing considerations and management for patients on Praletrexate 4. Discussion of a case study. Evaluation of this poster presentation would be that oncology nurses would have a better understanding of the use of praletrexate in T cell Lymphoma population. Nurses will be able to identify side effects of pralatreaxte and the need to initiate nursing intervention or need for medical attention from physician or midlevel practitioner. Nurses play an important role assessment and management of the possible side effects and complications associated with treatment with Praletrexate. This poster should serve as a brief review on major highlight points that nurses need to consider for T Cell patient receiving praletreaxeate as single agent or in combination therapy.
Repository Posting Date:
27-Oct-2011
Date of Publication:
27-Oct-2011
Conference Date:
2009
Conference Name:
34th Annual Oncology Nursing Society Congress
Conference Host:
Oncology Nursing Society
Conference Location:
San Antonio, Texas, USA
Note:
This is an abstract-only submission. If the author has submitted a full-text item based on this abstract, you may find it by browsing the Virginia Henderson Global Nursing e-Repository by author. If author contact information is available in this abstract, please feel free to contact him or her with your queries regarding this submission. Alternatively, please contact the conference host, journal, or publisher (according to the circumstance) for further details regarding this item. If a citation is listed in this record, the item has been published and is available via open-access avenues or a journal/database subscription. Contact your library for assistance in obtaining the as-published article.

Full metadata record

DC FieldValue Language
dc.type.categoryAbstracten_US
dc.typePresentationen_GB
dc.titleNew Agent Pralatrexate: Nursing Management and considerations on T cell Lymphoma patients receiving pralatrexateen_GB
dc.contributor.authorGuerrero, Mariaen_US
dc.contributor.authorLoggins-Coffman, Judyen_US
dc.author.detailsMaria Guerrero, RN, MSN, ANP-C, AOCNP, Nurse Practitioner, MD Anderson Cancer Center, Houston, Texas, USA, email: mdguerre@mdanderson.org; Judy Loggins-Coffman, RN, MDen_US
dc.identifier.urihttp://hdl.handle.net/10755/164977-
dc.description.abstractClinical/Evidence Based Practice: T cell Lymphoma represents a group of malignancies for which there has been little progress in treatment over the past years. T cell Lymphoma not only reveals a prognosis that may be worse than B cell Lymphoma, but T cell is a rare cancer (representing 10-15% of malignant lymphoma) little consensus can be established due to difficulties in finding enough patients to enroll for appropriate clinical studies. For this reason there is a strong demand to develop drugs and treatment regimens for T cell Lymphoma. In this poster we would like to discuss the new emerging drug Pralatrexate for the treatment of T Cell Lymphoma. The purpose of this poster is to provide an educational tool that the oncology nurse briefly discuss new drug praletrexate, its role in T cell lymphoma, side effects associated with this drug, as well as nursing considerations and 1. Discuss the role of Pralatrexate in the treatment of T Cell Lymphoma 2. Common side effects associated with Praletrexate 3. Nursing considerations and management for patients on Praletrexate 4. Discussion of a case study. Evaluation of this poster presentation would be that oncology nurses would have a better understanding of the use of praletrexate in T cell Lymphoma population. Nurses will be able to identify side effects of pralatreaxte and the need to initiate nursing intervention or need for medical attention from physician or midlevel practitioner. Nurses play an important role assessment and management of the possible side effects and complications associated with treatment with Praletrexate. This poster should serve as a brief review on major highlight points that nurses need to consider for T Cell patient receiving praletreaxeate as single agent or in combination therapy.en_GB
dc.date.available2011-10-27T12:10:22Z-
dc.date.issued2011-10-27en_GB
dc.date.accessioned2011-10-27T12:10:22Z-
dc.conference.date2009en_US
dc.conference.name34th Annual Oncology Nursing Society Congressen_US
dc.conference.hostOncology Nursing Societyen_US
dc.conference.locationSan Antonio, Texas, USAen_US
dc.description.noteThis is an abstract-only submission. If the author has submitted a full-text item based on this abstract, you may find it by browsing the Virginia Henderson Global Nursing e-Repository by author. If author contact information is available in this abstract, please feel free to contact him or her with your queries regarding this submission. Alternatively, please contact the conference host, journal, or publisher (according to the circumstance) for further details regarding this item. If a citation is listed in this record, the item has been published and is available via open-access avenues or a journal/database subscription. Contact your library for assistance in obtaining the as-published article.-
All Items in this repository are protected by copyright, with all rights reserved, unless otherwise indicated.